Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 4 studies | 26% ± 6% | |
microglial cell | 4 studies | 21% ± 1% | |
fibroblast | 4 studies | 17% ± 2% | |
epithelial cell | 3 studies | 28% ± 10% | |
type I pneumocyte | 3 studies | 21% ± 2% | |
GABAergic neuron | 3 studies | 33% ± 6% | |
glutamatergic neuron | 3 studies | 43% ± 6% | |
macrophage | 3 studies | 21% ± 5% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 4 studies | 28% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1095.70 | 1445 / 1445 | 100% | 21.91 | 183 / 183 |
lung | 100% | 1870.88 | 578 / 578 | 100% | 27.65 | 1155 / 1155 |
breast | 100% | 1515.10 | 459 / 459 | 100% | 30.91 | 1115 / 1118 |
brain | 100% | 1414.66 | 2633 / 2642 | 100% | 25.51 | 705 / 705 |
kidney | 100% | 1506.26 | 89 / 89 | 100% | 51.35 | 897 / 901 |
thymus | 100% | 1530.01 | 653 / 653 | 99% | 26.44 | 601 / 605 |
prostate | 100% | 1267.17 | 244 / 245 | 99% | 22.62 | 499 / 502 |
pancreas | 100% | 1267.37 | 328 / 328 | 99% | 33.82 | 176 / 178 |
uterus | 100% | 1610.83 | 170 / 170 | 99% | 23.15 | 453 / 459 |
bladder | 100% | 1267.81 | 21 / 21 | 99% | 22.27 | 497 / 504 |
stomach | 100% | 1638.71 | 359 / 359 | 99% | 19.30 | 282 / 286 |
intestine | 100% | 1462.94 | 966 / 966 | 98% | 21.58 | 517 / 527 |
liver | 100% | 2174.81 | 226 / 226 | 98% | 30.78 | 396 / 406 |
ovary | 100% | 1600.31 | 180 / 180 | 97% | 13.05 | 418 / 430 |
adrenal gland | 99% | 1048.25 | 256 / 258 | 97% | 20.11 | 223 / 230 |
skin | 100% | 1703.75 | 1809 / 1809 | 93% | 16.91 | 437 / 472 |
blood vessel | 100% | 2810.44 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 19.29 | 29 / 29 |
spleen | 100% | 2018.27 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 17.66 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 12.84 | 1 / 1 |
adipose | 100% | 1512.28 | 1203 / 1204 | 0% | 0 | 0 / 0 |
muscle | 98% | 702.34 | 785 / 803 | 0% | 0 | 0 / 0 |
heart | 94% | 940.45 | 813 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 82% | 1410.57 | 765 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 50% | 4.42 | 40 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0042472 | Biological process | inner ear morphogenesis |
GO_0010894 | Biological process | negative regulation of steroid biosynthetic process |
GO_0036316 | Biological process | SREBP-SCAP complex retention in endoplasmic reticulum |
GO_0042474 | Biological process | middle ear morphogenesis |
GO_0032933 | Biological process | SREBP signaling pathway |
GO_0060021 | Biological process | roof of mouth development |
GO_0006695 | Biological process | cholesterol biosynthetic process |
GO_0032869 | Biological process | cellular response to insulin stimulus |
GO_0060363 | Biological process | cranial suture morphogenesis |
GO_0006641 | Biological process | triglyceride metabolic process |
GO_0045717 | Biological process | negative regulation of fatty acid biosynthetic process |
GO_0032937 | Cellular component | SREBP-SCAP-Insig complex |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0140311 | Molecular function | protein sequestering activity |
GO_0005515 | Molecular function | protein binding |
GO_0008142 | Molecular function | oxysterol binding |
Gene name | INSIG2 |
Protein name | Insulin induced gene 2 Insulin-induced gene 2 protein (INSIG-2) |
Synonyms | |
Description | FUNCTION: Oxysterol-binding protein that mediates feedback control of cholesterol synthesis by controlling both endoplasmic reticulum to Golgi transport of SCAP and degradation of HMGCR . Acts as a negative regulator of cholesterol biosynthesis by mediating the retention of the SCAP-SREBP complex in the endoplasmic reticulum, thereby blocking the processing of sterol regulatory element-binding proteins (SREBPs) SREBF1/SREBP1 and SREBF2/SREBP2 . Binds oxysterol, including 22-hydroxycholesterol, 24-hydroxycholesterol, 25-hydroxycholesterol and 27-hydroxycholesterol, regulating interaction with SCAP and retention of the SCAP-SREBP complex in the endoplasmic reticulum . In presence of oxysterol, interacts with SCAP, retaining the SCAP-SREBP complex in the endoplasmic reticulum, thereby preventing SCAP from escorting SREBF1/SREBP1 and SREBF2/SREBP2 to the Golgi . Sterol deprivation or phosphorylation by PCK1 reduce oxysterol-binding, disrupting the interaction between INSIG2 and SCAP, thereby promoting Golgi transport of the SCAP-SREBP complex, followed by processing and nuclear translocation of SREBF1/SREBP1 and SREBF2/SREBP2 . Also regulates cholesterol synthesis by regulating degradation of HMGCR: initiates the sterol-mediated ubiquitin-mediated endoplasmic reticulum-associated degradation (ERAD) of HMGCR via recruitment of the reductase to the ubiquitin ligase RNF139 . . |
Accessions | Q9Y5U4 ENST00000245787.9 ENST00000411929.5 F8WCG8 |